| Not Yet Recruiting | Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias NCT07447817 | John Mascarenhas | Phase 2 |
| Recruiting | A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms NCT07469891 | Prelude Therapeutics | Phase 1 |
| Recruiting | Registry Platform Myelofibrosis and Anemia NCT06976918 | iOMEDICO AG | — |
| Recruiting | MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People NCT07362225 | MPN Research Foundation | — |
| Recruiting | A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosi NCT06343805 | Ajax Therapeutics, Inc. | Phase 1 |
| Recruiting | A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017) NCT06351631 | Merck Sharp & Dohme LLC | Phase 3 |
| Recruiting | Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition NCT06218628 | Fox Chase Cancer Center | Phase 1 |
| Unknown | Real World Evidence of Fedratinib Effectiveness in MF NCT05883904 | Gruppo Italiano Malattie EMatologiche dell'Adulto | — |
| Recruiting | A Post-Marketing Surveillance Study to Assess the Safety of Fedratinib in Korean Patients With Myelofibrosis NCT06073847 | Bristol-Myers Squibb | — |
| Recruiting | Asian Myeloproliferative Neoplasm (MPN) Registry NCT05882773 | The University of Hong Kong | — |
| Terminated | Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis NCT04854096 | NS Pharma, Inc. | Phase 2 |
| Recruiting | Study of Canakinumab in Patients With Myelofibrosis NCT05467800 | John Mascarenhas | Phase 2 |
| Recruiting | Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia NCT05320198 | Disc Medicine, Inc | Phase 1 / Phase 2 |
| Terminated | To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Sub NCT04551053 | Incyte Corporation | Phase 3 |
| Terminated | To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER- NCT04551066 | Incyte Corporation | Phase 3 |
| Active Not Recruiting | Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2) NCT04603495 | Novartis Pharmaceuticals | Phase 3 |
| Withdrawn | A Study of LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera or Acute Myeloid Leu NCT04896112 | Lynk Pharmaceuticals Co., Ltd | Phase 1 |
| Active Not Recruiting | INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to NCT04455841 | Incyte Corporation | Phase 1 / Phase 2 |
| Withdrawn | Study of Select Combinations in Adults With Myelofibrosis NCT04283526 | Novartis Pharmaceuticals | Phase 1 |
| Completed | A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM) NCT04173494 | Sierra Oncology LLC - a GSK company | Phase 3 |
| Terminated | Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors NCT03627403 | University of Utah | Phase 2 |
| Terminated | A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythem NCT03755518 | Celgene | Phase 3 |
| Completed | MPN-RC 118 AVID200 in Myelofibrosis NCT03895112 | John Mascarenhas | Phase 1 |
| Terminated | Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis NCT03373877 | Samus Therapeutics, Inc. | Phase 1 |
| Completed | Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary My NCT04884191 | CTI BioPharma | Phase 2 |
| Recruiting | A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or NCT03165734 | Swedish Orphan Biovitrum | Phase 3 |
| Completed | PD-1 Inhibition in Advanced Myeloproliferative Neoplasms NCT03065400 | John Mascarenhas | Phase 2 |
| Completed | Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients. NCT02966353 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera My NCT02124746 | Sierra Oncology LLC - a GSK company | Phase 2 |
| Terminated | Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia NCT02055781 | CTI BioPharma | Phase 3 |
| Completed | Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis NCT01969838 | Sierra Oncology LLC - a GSK company | Phase 3 |
| Terminated | Ruxolitinib Prior to Transplant in Patients With Myelofibrosis NCT01790295 | John Mascarenhas | Phase 2 |
| Completed | A Phase 2 Study of RO7490677 In Participants With Myelofibrosis NCT01981850 | Hoffmann-La Roche | Phase 2 |
| Terminated | Pacritinib Versus Best Available Therapy to Treat Myelofibrosis NCT01773187 | CTI BioPharma | Phase 3 |
| Completed | A Prospective, Two-arm, Non-interventional Study of JAKAVI® (Ruxolitinib) in Patients With Myelofibrosis NCT05044026 | Novartis Pharmaceuticals | — |
| Completed | Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential NCT01433445 | Novartis Pharmaceuticals | Phase 1 |
| Completed | Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis NCT01445769 | Incyte Corporation | Phase 2 |
| Completed | Safety Study Evaluating Twice-Daily Administration of Momelotinib in Primary Myelofibrosis or Post-Polycythemi NCT01423058 | Sierra Oncology LLC - a GSK company | Phase 1 / Phase 2 |
| Completed | Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Ve NCT01423851 | NS Pharma, Inc. | Phase 1 / Phase 2 |
| Completed | Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or NCT01236638 | Sierra Oncology LLC - a GSK company | Phase 2 |
| Completed | Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-esse NCT00935987 | Sierra Oncology LLC - a GSK company | Phase 1 / Phase 2 |